---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000074"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:10:45.241855+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ligand Q3 revenue $51.8M (+58% YoY); raises 2024 guidance to $160-165M revenue, $5.50-5.70 adj EPS

## Summary
- Q3 total revenues & other income $51.8M (vs $32.9M); royalties $31.7M (+33% YoY) on QARZIBA and FILSPARI growth.
- GAAP net loss from continuing ops $7.2M ($0.39 loss/sh); core adj net income $35.3M ($1.84/sh) vs $18.0M ($1.02).
- Raised 2024 guidance: revenue now $160-165M (prev $140-157M); adj EPS $5.50-5.70 (prev $5.00-5.50).
- Received $13.5M milestone upon Ohtuvayre commercial launch; cash & investments $219.6M including $63.3M in VKTX stock.
- Issued 334,325 shares under ATM at avg $104.70 for gross $35M; up to $65M remains available.

## SEC filing metadata
- accession: 0000886163-24-000074
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000074/0000886163-24-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000074/lgnd-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000074
- JSON: https://secwatch.observer/filing/0000886163-24-000074.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.